Algeta's Phase II clinical study of Alpharadin highlights its potential as a treatment for bone metastases in prostate cancer patients, meets primary endpoint in bone marker analysis.

(From Chemical Business NewsBase - Press Release)

Algeta ASA announced that an analysis of the biomarker data from a Phase II trial of its lead product Alpharadin (radium-223) continues to demonstrate its potential as a treatment for bone metastases in hormone-refractory prostate cancer (HRPC) patients. Data from this trial (BC1-02) were presented at the 2006 Prostate Cancer Symposium in San Francisco, CA. Algeta is conducting trial BC1-02 as part of its Phase II clinical programme for Alpharadin, a novel radiopharmaceutical based on the alpha particle emitter radium-223, which naturally targets and attacks skeletal metastases. The double-blind placebo-controlled trial …